Degarelix for prostate cancer
Author:
Publisher
Informa Healthcare
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://www.tandfonline.com/doi/pdf/10.1517/13543780902954713
Reference47 articles.
1. Cancer Statistics, 2008
2. Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer
3. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
4. Survival in Men With Nonmetastatic Prostate Cancer Treated With Hormone Therapy: A Quantitative Systematic Review
5. Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Relugolix in the management of prostate cancer;Expert Review of Anticancer Therapy;2022-07-27
2. The industrial design, translation, and development strategies for long-acting peptide delivery;Expert Opinion on Drug Delivery;2022-07-21
3. Pharmacological characterization of linzagolix, a novel, orally active, non‐peptide antagonist of gonadotropin‐releasing hormone receptors;Clinical and Experimental Pharmacology and Physiology;2022-07-12
4. Estrus Suppression in Dogs;Veterinary Clinics of North America: Small Animal Practice;2018-07
5. The Relationship of Industry Payments to Prescribing Behavior: A Study of Degarelix and Denosumab;Urology Practice;2017-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3